AstraZeneca, Guardant Health to develop CDx tests for oncology products
Precision oncology firm Guardant Health has entered into a multi-year agreement with AstraZeneca to develop companion diagnostic (CDx)…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Dec 18
Precision oncology firm Guardant Health has entered into a multi-year agreement with AstraZeneca to develop companion diagnostic (CDx)…
14 Dec 18
Francis Medical, a company engaged in the development of developing urological cancer treatments, has raised $18m Series A…
13 Dec 18
Roche has collaborated with Merck on the development of a companion diagnostic test to identify patients eligible for…
13 Dec 18
InterVenn BioSciences has secured institutional investment of $9.4m led by biotech investor Genoa Ventures, with participation from True…
06 Dec 18
A project, led by Genomics England in partnership with NHS England, has sequenced 100,000 whole genomes from NHS…
05 Dec 18
Siemens Healthineers has invested $300m in the Walpole laboratory diagnostics manufacturing facility, located in the US state of…
05 Dec 18
Molecular diagnostics firm Asuragen has secured CE mark approval for its AmplideX DM1 Dx kit, which is developed…
03 Dec 18
Qiagen and NeoGenomics have signed an agreement to speed up the availability of companion diagnostics that allow precision…
28 Nov 18
Quest Diagnostics has agreed to acquire the clinical laboratory services business of Boyce and Bynum Pathology Laboratories (BBPL),…
28 Nov 18
Molecular diagnostic firm Mesa Biotech has secured 510(k) clearance from the US Food and Drug Administration (FDA) for…